Tag: Vemurafenib
1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients.
2. Post hoc analysis suggested minimal residual disease negative status and the lack of prior v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors exposure were associated with better survival.
Evidence Rating Level: 2...
Click to read the study in the European Journal of Cancer.
1. Participants with BRAF V600 mutation-positive small-cell lung cancer, Erdheim Chester Disease (ECD) and Langerhan’s-Cell Histiocytosis (LCH) demonstrated a modest but statistically significant response rate to treatment with vemurafenib.
2. Participants with BRAF V600 mutation-positive colorectal cancer did not demonstrate appreciable response rates to vemurafenib monotherapy or vemurafenib with cetuximab...